Results 1 to 10 of about 74,974 (313)

Systematic Review of Parkinsonism in Cerebrotendinous Xanthomatosis

Neurology International
Background: Cerebrotendinous Xanthomatosis (CTX) is a rare, inherited metabolic disease caused by pathogenic variants in CYP27A1. The clinical presentation of this progressive disease includes cognitive deficits, ataxia, peripheral neuropathy, and ...
Jennifer Hanson, Penelope E. Bonnen
doaj   +2 more sources

Diagnostics and treatment of vascular parkinsonism [PDF]

Саратовский научно-медицинский журнал, 2010
The article presents clinical syndromic classification of parkinsonism in relation to etiological factors. It also studies epidemiologic and historical aspects of vascular parkinsonism.
V.V. Yudina, O.N. Voskresenskaya, G.K. Yudina   +2 more
doaj   +1 more source

Familial Parkinson’s Disease/Parkinsonism [PDF]

BioMed Research International, 2015
Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by parkinsonism (bradykinesia, resting tremor, rigidity, and postural instability) with good response to L-dopa. Although the majority of PD patients are sporadic, it is now clear that genetic factors contribute to the pathogenesis of PD.
Hiroyuki Tomiyama, Suzanne Lesage, Eng-King Tan, Beom S. Jeon   +3 more
openaire   +2 more sources

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

Journal of Neuroinflammation, 2023
Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1.
Max Stevenson, Rency Varghese, Michaeline L. Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R. Scott Turner, Charbel Moussa   +7 more
doaj   +1 more source

Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study

Neuropsychiatric Disease and Treatment, 2015
Seyed-Mohammad Fereshtehnejad,1,2 Mahdiyeh Shafieesabet,3 Arash Rahmani,4 Ahmad Delbari,1,5 Johan Lökk1,6 1Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Stockholm, Sweden ...
Fereshtehnejad SM, Shafieesabet M, Rahmani A, Delbari A, Lökk J   +4 more
doaj   +1 more source

Clinical neurophysiology of Parkinson’s disease and parkinsonism [PDF]

Clinical Neurophysiology Practice, 2022
This review is part of the series on the clinical neurophysiology of movement disorders. It focuses on Parkinson's disease and parkinsonism. The topics covered include the pathophysiology of tremor, rigidity and bradykinesia, balance and gait disturbance and myoclonus in Parkinson's disease.
Chen, Robert, Berardelli, A., Bhattacharya, A., Bologna, M., Chen, K.S., Fasano, A., Helmich, R.C.G., Helmich, R.C.G., Hutchison, W.D., Kamble, N., Kühn, A.A., Macerollo, A., Neumann, W.J., Pal, P.K., Paparella, G., Suppa, A., Udupa, K.   +16 more
openaire   +4 more sources

Viral Parkinsonism: An underdiagnosed neurological complication of Dengue virus infection

PLoS Neglected Tropical Diseases, 2022
Dengue virus (DENV) is a flavivirus that is a significant cause of human disease costing billions of dollars per year in medical and mosquito control costs. It is estimated that up to 20% of DENV infections affect the brain.
Hannah K. Hopkins, Elizabeth M. Traverse, Kelli L. Barr   +2 more
doaj   +2 more sources

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for ...
Fernando L. Pagan, Yasar Torres‐Yaghi, Michaeline L. Hebron, Barbara Wilmarth, R. Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa   +8 more
doaj   +1 more source

Progress on diagnosis and treatment of functional parkinsonism

Chinese Journal of Contemporary Neurology and Neurosurgery, 2023
Functional parkinsonism (FP) is a disorder caused by psychological factors rather than neurodegeneration. Functional parkinsonism has a great influence on patients' quality of life and daily function. However, due to overlapping with some of the symptoms
HUANG Pei, WANG Gang
doaj   +1 more source

Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study

Journal of Parkinson’s Disease, 2023
Background: Sleep disturbances are common in parkinsonian disorders; however, whether sleep disorders affect individuals with early-onset parkinsonism and whether they differ from individuals with typical-onset parkinsonism is unknown.
Stuart J. McCarter, Emanuele Camerucci, Aidan F. Mullan, Cole D. Stang, Pierpaolo Turcano, Erik K. St. Louis, Bradley F. Boeve, Rodolfo Savica   +7 more
doaj   +1 more source